Trpc ion channel inhibitors for use in therapy
AssigneeUniversity of Leeds
InventorsDavid John BEECH, Richard James FOSTER, Sin Ying CHEUNG, Baptiste Michel RODE
Life of this patent
Estimating the term…
Abstract
Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.
Claims28
A method of treatment or prophylaxis of a condition selected from obesity, insulin resistance, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a subject in need thereof, the method comprising administering to the subject an inhibitor which directly targets a Transient Receptor Potential Canonical (TRPC) ion channel comprising TRPC4 as present in adipocytes.
(canceled)
(canceled)
(canceled)
(canceled)
A cosmetic method of reducing or inhibiting excess weight gain in a subject in need thereof, the method comprising administering to the subject an inhibitor which directly targets a Transient Receptor Potential Canonical (TRPC) ion channel comprising TRPC4 as present in adipocytes.
(canceled)
Dependencies are inferred from the claim text.